Close Menu

cervical cancer

The French firm is assessing the Roche Cobas HPV test in preparation for a global Phase III clinical trial of its own therapeutic HPV vaccine.

The company and the hospital will conduct a clinical study into the detection and prevention of the disease.

Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.

The Hologic-funded model predicted co-testing would lead to a lifetime savings of $39 per woman, with high cancer detection sensitivity and fewer false positive results.

IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.

The Netherlands is expected to be the first country to replace Pap cytology with HPV screening for first-line primary screening for cervical cancer.

HPV diversity could be caused by innate and adaptive immune responses and may have implications for understanding why some lesions become malignant. 

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

This Week in PLOS

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

The conditional licensure is the latest for the firm's FISH-based HPV-Associated test for cervical cancer.

Pages

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.